Abstract: Agonists for the TRPM-8 receptor, more particularly one or more substances selected from the group of, for example, linalool, geraniol, hydroxycitronellal, WS-3 (N-ethyl-p-menthane-3-carboxamide), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide), Frescolat MAG (1,4-dioxaspiro[4.5]decane-2-methanol), Frescolat ML (menthyl lactate), Coolact P (5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol) and Cooling Agent 10 (menthoxypropanediol), for use as medicaments to counter atopic dermatitis.

Abstract: Alkylamidothiazoles of general formula (I), wherein R 1=—C1-C24 alkyl (linear and branched), —C1-C24 alkenyl (linear and branched), —C1-C8 cycloalkyl, —C1-C8 cycloalkyl-alkylhydroxy, —C1-C24 alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24 alkylaryl (linear and branched), —C1-C24 alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24 alkyl-heteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24 alkyl morpholino, —C1-C24 alkyl piperidino, —C1-C24 alkyl piperazino, —C1-C24 alkyl-piperazino-N-alkyl, as well as cosmetic or dermatological preparations having an effective content of one or more alkylamidothiazoles, as well as the use thereof for the cosmetic or dermatological treatment and/or prophylaxis of undesired skin pigmentation.

Abstract: The invention relates to active ingredient combinations of magnolia bark extract and hyaluronic acid, cosmetic and/or dermatological preparations containing said active ingredient combinations and to the use thereof for the cosmetic and/or dermatological treatment and/or prophylaxis of cellulite and/or the appearance form of skin aging.

Abstract: Agonists for the TRPM-8 receptor, more particularly one or more substances selected from the group of, for example, linalool, geraniol, hydroxycitronellal, WS-3 (N-ethyl-p-menthane-3-carboxamide), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide), Frescolat MAG (1,4-dioxaspiro[4.5]decane-2-methanol), Frescolat ML (menthyl lactate), Coolact P (5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol) and Cooling Agent 10 (menthoxypropanediol), for use as medicaments to counter atopic dermatitis.

Abstract: The invention relates to active ingredient combinations of magnolia bark extract and hyaluronic acid, cosmetic and/or dermatological preparations containing said active ingredient combinations and to the use thereof for the cosmetic and/or dermatological treatment and/or prophylaxis of cellulite and/or the appearance form of skin aging.

Abstract: Alkylamidothiazoles of general formula (I), wherein R 1=—C1-C24 alkyl (linear and branched), —C1-C24 alkenyl (linear and branched), —C1-C8 cycloalkyl, —C1-C8 cycloalkyl-alkylhydroxy, —C1-C24 alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24 alkylaryl (linear and branched), —C1-C24 alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24 alkyl-heteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24 alkyl morpholino, —C1-C24 alkyl piperidino, —C1-C24 alkyl piperazino, —C1-C24 alkyl-piperazino-N-alkyl, as well as cosmetic or dermatological preparations having an effective content of one or more alkylamidothiazoles, as well as the use thereof for the cosmetic or dermatological treatment and/or prophylaxis of undesired skin pigmentation.

Abstract: The present invention relates to compounds of formula (I) below having pharmacological activity towards the sigma (?) receptor, and more particularly to spiro-pyrano-pyrazole compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis.

Abstract: The present invention relates to compounds having the structural formula below and pharmacological activity towards the sigma (?) receptor, and more particularly to pyrano-pyrazole-amines, to processes of preparing such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis.